Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
University of California San Diego · Center for Personalized Cancer Treatment · +1 more institution
Abstract
Abstract Immunotherapy induces durable responses in a subset of patients with cancer. High tumor mutational burden (TMB) may be a response biomarker for PD-1/PD-L1 blockade in tumors such as melanoma and non–small cell lung cancer (NSCLC). Our aim was to examine the relationship between TMB and outcome in diverse cancers treated with various immunotherapies. We reviewed data on 1,638 patients who had undergone comprehensive genomic profiling and had TMB assessment. Immunotherapy-treated patients (N = 151) were analyzed for response rate (RR), progression-free survival (PFS), and overall survival (OS). Higher TMB was independently associated with better outcome parameters (multivariable analysis). The RR for…
Citation impact
- FWCI
- 102.99
- Percentile
- 100%
- References
- 58
Authors
9- AMAaron M. GoodmanCorresponding
University of California San Diego, Center for Personalized Cancer Treatment
- SKShumei Kato
University of California San Diego, Center for Personalized Cancer Treatment
- LBLyudmila Bazhenova
University of California San Diego
- SPSandip Pravin Patel
University of California San Diego
- GMGarrett M. Frampton
GlobalFoundries (United States)
Topics & keywords
- Medicine
- Internal medicine
- Immunotherapy
- Oncology
- Blockade
- Lung cancer
- Cancer
- Receptor
- Good health and well-being